(Q42628400)

4 November 2017

title

A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group (English)

1 reference

4 November 2017

1 reference

1 reference

Davidson M

1

1 reference

4 November 2017

Harvey PD

2

1 reference

4 November 2017

Vervarcke J

3

1 reference

4 November 2017

Gagiano CA

4

1 reference

4 November 2017

De Hooge JD

5

1 reference

4 November 2017

Bray G

6

1 reference

4 November 2017

Dose M

7

1 reference

4 November 2017

Barak Y

8

1 reference

4 November 2017

Haushofer M

9

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

International Journal of Geriatric Psychiatry

4 November 2017

published in

1 reference

4 November 2017

volume

15

1 reference

4 November 2017

issue

6

1 reference

4 November 2017

page(s)

506-514

1 reference

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Severity of symptoms in chronically institutionalized geriatric schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

The effect of risperidone on cognition in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200006%2915%3A6%3C506%3A%3AAID-GPS146%3E3.0.CO%3B2-V

10.1002/1099-1166(200006)15:6<506::AID-GPS146>3.0.CO;2-V

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference